Generic Name: belinostat (be LIN oh stat)
Brand Name: Beleodaq
What is belinostat?
Belinostat is a cancer medication that interferes with the growth and spread of cancer cells in the body.
Belinostat is used to treat peripheral T-cell lymphoma that has relapsed or has not responded to other treatments.
Belinostat was approved by the US Food and Drug Administration (FDA) on an "accelerated" basis. In clinical studies, non-small cell lung tumors responded to this medicine. However, it has not been shown that belinostat can improve symptoms or lengthen survival time.
Belinostat may also be used for purposes not listed in this medication guide.
What is the most important information I should know about belinostat?
You should not use belinostat if you have an active infection.
What should I discuss with my healthcare provider before receiving belinostat?
You should not use belinostat if you are allergic to it, or if you have:
an active infection.
To make sure belinostat is safe for you, tell your doctor if you have:
kidney disease; or
if you have received high-dose or intensive chemotherapy in the past.
Do not use belinostat if you are pregnant. It could harm the unborn baby. Use effective birth control to prevent pregnancy, and tell your doctor if you become pregnant during treatment.
It is not known whether belinostat passes into breast milk or if it could harm a nursing baby. You should not breast-feed while using this medicine.
How is belinostat given?
Belinostat is injected into a vein through an IV. A healthcare provider will give you this injection.
Belinostat must be injected slowly, and the IV infusion can take at least 30 minutes to complete.
Belinostat is given in a 21-day treatment cycle, and you may only receive the medicine during the first 5 days of each cycle. Your doctor will determine how long to treat you with belinostat.
You may be given medication to prevent nausea, vomiting, or diarrhea while you are receiving belinostat.
You will need frequent medical tests to be sure this medicine is not causing harmful effects. Your blood will need to be tested every week during each treatment cycle. Your cancer treatments may be delayed based on the results of these tests.
Belinostat can lower blood cells that help your body fight infections and help your blood to clot. This can make it easier for you to bleed from an injury or get sick from being around others who are ill.
What happens if I miss a dose?
Take the missed dose as soon as you remember. Skip the missed dose if it is almost time for your next scheduled dose. Do not take extra medicine to make up the missed dose.
What happens if I overdose?
Since this medicine is given by a healthcare professional in a medical setting, an overdose is unlikely to occur.
What should I avoid while receiving belinostat?
Avoid being near people who are sick or have infections. Tell your doctor at once if you develop signs of infection.
Avoid activities that may increase your risk of bleeding or injury. Use extra care to prevent bleeding while shaving or brushing your teeth.
This medicine can pass into body fluids (urine, feces, vomit). For at least 48 hours after you receive a dose, avoid allowing your body fluids to come into contact with your hands or other surfaces. Caregivers should wear rubber gloves while cleaning up a patient's body fluids, handling contaminated trash or laundry or changing diapers. Wash hands before and after removing gloves. Wash soiled clothing and linens separately from other laundry.
Belinostat side effects
Get emergency medical help if you have signs of an allergic reaction: hives; difficult breathing; swelling of your face, lips, tongue, or throat.
Call your doctor at once if you have:
severe or continued vomiting or diarrhea;
fever, chills, flu symptoms, swollen gums, painful mouth sores, pain when swallowing, skin sores;
stabbing chest pain, wheezing, trouble breathing, cough with yellow or green mucus;
pain or burning when you urinate;
easy bruising, unusual bleeding (nose, mouth, vagina, or rectum), purple or red pinpoint spots under your skin;
liver problems--nausea, upper stomach pain, itching, tired feeling, loss of appetite, dark urine, clay-colored stools, jaundice (yellowing of the skin or eyes); or
signs of tumor cell breakdown--lower back pain, blood in your urine, little or no urinating; numbness or tingly feeling around your mouth; muscle weakness or tightness; fast or slow heart rate, weak pulse, feeling short of breath; confusion, fainting.
Common side effects may include:
tired feeling; or
anemia (low red blood cells)--pale skin, feeling light-headed or short of breath, rapid heart rate, trouble concentrating.
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
Belinostat dosing information
Usual Adult Dose for Lymphoma:
1,000 mg/m2 IV over 30 minutes once daily on days 1 to 5 of a 21-day cycle
Duration of therapy: Repeat cycle every 21 days until disease progression or unacceptable toxicity.
-Dose reduction, discontinuation, or interruption of therapy may be needed to manage adverse reactions.
Use: Relapsed or refractory peripheral T-cell lymphoma
What other drugs will affect belinostat?
Other drugs may interact with belinostat, including prescription and over-the-counter medicines, vitamins, and herbal products. Tell each of your health care providers about all medicines you use now and any medicine you start or stop using.
More about belinostat
- Side Effects
- During Pregnancy
- Dosage Information
- Drug Interactions
- Support Group
- En Español
- 0 Reviews – Add your own review/rating
- Drug class: histone deacetylase inhibitors
Other brands: Beleodaq
Related treatment guides
Where can I get more information?
- Your pharmacist can provide more information about belinostat.
- Remember, keep this and all other medicines out of the reach of children, never share your medicines with others, and use this medication only for the indication prescribed.
- Disclaimer: Every effort has been made to ensure that the information provided by Cerner Multum, Inc. ('Multum') is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Multum information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Multum does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Multum's drug information does not endorse drugs, diagnose patients or recommend therapy. Multum's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners. The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Multum does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Copyright 1996-2012 Cerner Multum, Inc. Version: 1.02.
Date modified: December 03, 2017
Last reviewed: December 16, 2015